Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug

Back to Search
Print
Bookmark Trial

NCT00644839

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Miami, Florida, 33169, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy

- Body Mass Index (BMI) of 26.6 to 40.5 kg/m2.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Non-prescribed use of drugs or abuse of recreational drugs; recent treatment with
experimental drugs or herbal experiments; EKG and blood pressure measurements falling
outside of protocol-specified limits; history of regular alcohol or tobacco use
exceeding protocol-specified limits; medically important health conditions; recent use
of prescription or non-prescription medications.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

ObesityPharmacokinetics Of Tigecycline In Morbidly Obese Subjects
NCT01560143
  1. Albany, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityRandomized, Controlled, Open, Comparative Intervention Study for Obesity Prevention in Children
NCT00438555
  1. Petach Tikva,
ALL GENDERS
5 Years+
years
MULTIPLE SITES
ObesitySafety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
NCT00331175
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityA 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
NCT00391196
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Huntsville, Alabama
  4. Mobile, Alabama
  5. Chandler, Arizona
  6. Mesa, Arizona
  7. Phoenix, Arizona
  8. Fresno, California
  9. Palm Springs, California
  10. Tustin, California
  11. Walnut Creek, California
  12. New Britain, Connecticut
  13. Washington, District of Columbia
  14. Orlando, Florida
  15. West Palm Beach, Florida
  16. Honolulu, Hawaii
  17. Gurnee, Illinois
  18. Madisonville, Kentucky
  19. Baton Rouge, Louisiana
  20. Metairie, Louisiana
  21. Auburn, Maine
  22. Scarborough, Maine
  23. Baltimore, Maryland
  24. Bay City, Michigan
  25. Troy, Michigan
  26. Edina, Minnesota
  27. Jefferson City, Missouri
  28. Albuquerque, New Mexico
  29. Buffalo, New York
  30. New York, New York
  31. Greenville, North Carolina
  32. Beaver, Pennsylvania
  33. Cumberland, Rhode Island
  34. Pawtucket, Rhode Island
  35. Greer, South Carolina
  36. Bristol, Tennessee
  37. Nashville, Tennessee
  38. Dallas, Texas
  39. Dallas, Texas
  40. San Antonio, Texas
  41. San Antonio, Texas
  42. Renton, Washington
  43. Morgantown, West Virginia
  44. Buenos Aires,
  45. Buenos Aires,
  46. Buenos Aires,
  47. Garran, Australian Capital Territory
  48. Wollongong, New South Wales
  49. Adelaide, South Australia
  50. Box Hill, Victoria
  51. Nedlands, Western Australia
  52. Curitiba, PR
  53. Porto Alegre, RS
  54. São Paulo, SP
  55. São Paulo, SP
  56. São Paulo, SP
  57. São Paulo, SP
  58. Red Deer, Alberta
  59. Coquitlam, British Columbia
  60. Winnipeg, Manitoba
  61. Thornhill, Ontario
  62. Charlottetown, Prince Edward Island
  63. L'Ancienne-Lorette, Quebec
  64. Saint-Marc-des-Carrières, Quebec
  65. Breclav,
  66. Ceske Budejovice,
  67. Olomouc,
  68. Praha 2,
  69. Praha 4 - Krc,
  70. Berlin,
  71. Dresden,
  72. Duesseldorf,
  73. Hamburg,
  74. Leipzig,
  75. Mittweida,
  76. Tampico, Cd. Madero
  77. Mexico, DF
  78. Guadalajara, Jalisco
  79. Monterrey, Nuevo León
  80. Banska Bystrica,
  81. Bratislava,
  82. Lubochna,
  83. Nitra,
  84. Goteborg,
  85. Huddinge,
  86. Edinburgh, Lothian
  87. Bath, Somerset
  88. Coventry,
  89. Dumfries,
  90. Dundee,
  91. Luton,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug
Official Title  ICMJE A Phase 1, Open-Label, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Omeprazole On The Single Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects
Brief Summary Experiment in the test tube indicated that CP-945,598 becomes less soluble with increase of pH (less acidity). Changes in stomach acid levels may affect the solubility of CP-945,598, therefore, alters its availability in the blood. Omeprazole decreases acid levels in stomach. This study will compare the time course of drug concentrations in the body, safety, and tolerability of CP-945,598 given with and without omeprazole.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Obesity
Intervention  ICMJE
  • Drug: CP-945,598
    Administration of CP-945,598 alone in period 1
  • Drug: CP-945,598
    Adminstration of CP-945,598 with omeprazole in period 2
Study Arms  ICMJE Experimental: CP-945,598
Interventions:
  • Drug: CP-945,598
  • Drug: CP-945,598
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 21, 2008)		28
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 2008
Actual Primary Completion Date July 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy
  • Body Mass Index (BMI) of 26.6 to 40.5 kg/m2.

Exclusion Criteria:

  • Non-prescribed use of drugs or abuse of recreational drugs; recent treatment with experimental drugs or herbal experiments; EKG and blood pressure measurements falling outside of protocol-specified limits; history of regular alcohol or tobacco use exceeding protocol-specified limits; medically important health conditions; recent use of prescription or non-prescription medications.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00644839
Other Study ID Numbers  ICMJE A5351042
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP